Shares of Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) rose 34.9% on Wednesday . The company traded as high as $0.60 and last traded at $0.56. Approximately 16,694 shares changed hands during trading, an increase of 26% from the average daily volume of 13,224 shares. The stock had previously closed at $0.42.
Defence Therapeutics Stock Performance
The stock has a 50 day moving average of $0.39 and a 200-day moving average of $0.45.
About Defence Therapeutics
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Featured Stories
- Five stocks we like better than Defence Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- Oracle Announces Game-Changing News for the AI Industry
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Overbought Stocks Explained: Should You Trade Them?
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
